EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3825-3839

  Kuroda, Shinji ^a   Tam, Justina ^b   Roth, Jack A ^a   Sokolov, Konstantin ^b   Ramesh, Rajagopal ^a,c  

^a Department of Thoracic and Cardiovascular Surgery ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Autophagy; Epidermal growth factor receptor; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAGNETITE NANOPARTICLE;

ANIMAL; APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; NUDE MOUSE; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MAGNETITE NANOPARTICLES; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905972790     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S65990     Document Type: Article

References (50)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2000;55:161-171.
2. Cuenca AG, Jiang H, Hochwald SN, et al. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107:459-466.
3. Jain KK. Recent advances in nanooncology. Technol Cancer Res Treat. 2008;7:1-13.
4. Sokolov K, Follen M, Aaron J, et al. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 2003;63:1999-2004.
5. Powell AC, Paciotti GF, Libutti SK. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol. 2010; 624:375-384.
6. Leuschner C, Kumar CS, Hansel W, et al. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat. 2006;99:163-176.
7. Li Z, Kawashita M, Araki N, et al. Preparation of magnetic iron oxide nanoparticles for hyperthermia of cancer in a FeCl2-NaNO3-NaOH aqueous system. J Biomater Appl. 2011;25:643-661.
8. Veale D, Kerr N, Gibson GJ, Harris AL. Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res. 1989;49:1313-1317.
9. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-6565.
10. DeGrendele H. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva, OSI-774), in the treatment of bronchioloalveolar carcinoma. Clin Lung Cancer. 2003;5:83-85.
11. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006; 12:4441s-4445s.
12. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and ceuximab plus irinotecan in irinotecan-refractory metatstatic colorectal cancer. N Engl J Med. 2004;351:337-345.
14. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-1500.
15. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005; 23:2556-2568.
16. Yokoyama T, Tam J, Kuroda S, et al. EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells. PLoS One. 2011;6: e25507.
17. Lyon JL, Fleming DA, Stone MB, Schiffer P, Williams ME. Synthesis of Fe oxide core/Au shell nanoparticles by iterative hydroxylamine seeding. Nano Letters. 2004;4:719-723.
18. Kumar S, Aaron J, Sokolov K. Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties. Nat Protoc. 2008; 3:314-320.
19. Oida Y, Gopalan B, Miyahara R, et al. Inhibition of nuclear factorkappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogenactivated protein kinase kinase kinase 1 activation. Mol Cancer Ther. 2007;6:1440-1449.
20. Aoki H, Kondo Y, Aldape K, et al. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy. 2008;4:467-475.
21. Ramesh R, Saeki T, Templeton NS, et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther. 2001;3:337-350.
22. Gooi HC, Hounsell EF, Lax I, et al. The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3C1B12 to the epidermal growth factor receptor of A431 cells. Biosci Rep. 1985;5:83-94.
23. Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol. 2008;3:145-150.
24. Sato K, Tsuchichara K, Fujii S, et al. Autophagy is activated in colorectral cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 2007;67:9677-9684.
25. Li JJ, Hartono D, Ong CN, Bay BH, Yung LY. Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials. 2010; 31:5996-6003.
26. Ma X, Wu Y, Jin S, et al. Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment. ACS Nano. 2011;5:8629-8639.
27. Zhao Y, Howe JL, Yu Z, et al. Exposure to titanium dioxide nanoparticles induces autophagy in primary human keratinocytes. Small. 2013;9:387-392.
28. Bexiga MG, Varela JA, Wang F, et al. Cationic nanoparticles induce caspase 3-, 7-and 9-mediated cytotoxicity in a human astrocytoma cell line. Nanotoxicology. 2011;5:557-567.
29. Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res. 2011;71:6261-6269.
30. González JE, Barquinero JF, Lee M, García O, Casaco A. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther. 2012;13:71-76.
31. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol. 2005;76:157-161.
32. Alarifi S, Ali D, Alkahtani S, et al. Induction of oxidative stress, DNA damage, and apoptosis in a malignant human skin melanoma cell line after exposure to zinc oxide nanoparticles. Int J Nanomedicine. 2013;8:983-993.
33. Duan J, Yu Y, Li Y, et al. Toxic effect of silica nanoparticles on endothelial cells through DNA damage response via Chk1-dependent G2/M checkpoint. PLoS One. 2013;8:e62087.
34. Wan R, Mo Y, Feng L, et al. DNA damage caused by metal nanoparticles: involvement of oxidative stress and activation of ATM. Chem Res Toxicol. 2012;25:1402-1411.
35. Bonner WM, Redon CE, Dickey JS, et al. Gamma H2AX and cancer. Nat Rev Cancer. 2008;8:957-967.
36. Munshi A, Tanaka T, Hobbs ML, et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006;5:1967-1974.
37. Li JJ, Zou L, Hartono D, et al. Gold nanoparticles induce oxidative damage in lung fibroblasts in vitro. Adv Mater. 2008;20:138-142.
38. Shubayev VI, Pisanic TR 2nd, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009;61:467-477.
39. Singh N, Manshian B, Jenkins GJ, et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials. 2009;30:3891-3914.
40. Wang S, Li W, Xue Z, et al. Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinog. 2013;52:900-907.
41. Belli M, Sapora O, Tabocchini MA. Molecular targets in cellular response to ionizing radiation and implications in space radiation protection. J Radiat Res. 2002;43 Suppl:S13-S19.
42. Stark GR, Taylor WR. Control of the G2/M transition. Mol Biotechnol. 2006;32:227-248.
43. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316-323.
44. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547-566.
45. Mroz RM, Schins RP, Li H, et al. Nanoparticle-driven DNA damage mimics irradiation-related carcinogenesis pathways. Eur Respir J. 2008; 31:241-251.
46. AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano. 2009;3:279-290.
47. Yamane K, Chen J, Kinsella TJ. Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint. Cancer Res. 2003;63:3049-3053.
48. Tse AN, Schwartz GK. Potentiation of cytotoxicity of topoisomerase 1 poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 2004;64:6635-6644.
49. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene. 2001;20:7453-7463.
50. Tao Y, Leteur C, Yang C, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle. 2009;8:1196-1205.